NEWS
Free Institutional Consultancy Services
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Zalcman Gerard
Université Paris Cité - Paris / France
Others
AD Scientific Index ID: 4991112
Paris City University
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Zalcman Gerard's MOST POPULAR ARTICLES
1-)
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ... Science 359 (6371), 91-97, 2018 36562018
2-)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung CancerBJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...New England Journal of Medicine 371 (23), 2167-2177, 201433392014
3-)
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer VJ Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, ... New England Journal of medicine 350 (4), 351-60, 2004 2883*2004
4-)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.New England Journal of Medicine 376 (25), 2415-2426, 201726102017
5-)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.New England Journal of Medicine 376 (25), 2415-2426, 201726012017
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept